CenTrial Logo

Can Tranexamic Acid Reduce Blood Loss During Cesarean Section?


Clinical trial investigates reducing blood loss during cesarean section

A recent clinical trial has investigated the effect of a drug called tranexamic acid in reducing blood loss during cesarean section.

A C-section (or cesarean birth) is a surgical procedure used to deliver a baby when a vaginal delivery can't be done safely. Cesarean section is the surgical delivery of a baby through a cut (incision) made in the mother's abdomen and uterus. It is performed when doctors believe that it is safer for the mother, the baby, or both. Increasingly women are making an informed choice of getting a C-section instead of a normal vaginal delivery due to the fear of pain encountered during normal delivery.

Postpartum hemorrhage, or excessive bleeding after childbirth, is a serious complication that can lead to maternal death. It is more common in women who have had multiple cesarean sections.

Tranexamic Acid (TXA) is a medication used to prevent excessive bleeding during surgical procedures. However, its use during C-sections is controversial as the data available is insufficient to justify its use.

A clinical trial was conducted recently aimed at investigating the effect of using tranexamic acid to reduce blood loss during cesarean section. 

The clinical study published in the American Journal of Obstetrics and Gynecology involved 110 women undergoing their 2nd or 3rd C sections divided into two groups. 55 women received 1g of tranexamic acid just before and after surgery while the remaining 55 women did not receive this drug. The women were followed for 24h at the end of which blood loss was calculated by laboratory testing.

Are you interested in clinical trials near you?

You can receive free notification of a trial for this, or any other condition, by completing a short confidential health profile.
Find a clinical trial near me
The results of the clinical trial showed that the average blood loss in the tranexamic group was 2272 ml compared to the other group in which the average blood loss was 2407 ml.

These results demonstrated that tranexamic acid did not significantly reduce blood loss during the C-section as the percentage of blood loss in both groups was similar.

However, the results of this clinical study did show that the risk of blood clots in the blood vessels of the patients receiving tranexamic acid was lower than in the other group.

The findings of this study have important implications for clinical practice, particularly for women who have had multiple cesarean deliveries as it shows that the use of tranexamic acid in these patients is not justified and other treatments for reducing blood loss should be sought out.

In conclusion, this clinical study has highlighted that tranexamic acid should not be used to reduce blood loss during cesarean section as the results do not show any benefit to justify its use. Furthermore, it emphasizes that new drugs should be sought for the reduction of blood loss. 

Share this article with a friend:

Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

20,000 clinical trials are seeking participants.
Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.

This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.